Test Price
1,200 AED✅ Home Collection Available
BCR‑ABL1 Quantitative (CML MRD1) Monitoring Test in UAE | 1,200 AED | 2026 DHA Guidelines
تحليل BCR‑ABL1 الكمي لمراقبة المرض المتبقي الأدنى في سرطان الدم النقوي المزمن (CML MRD1) في الإمارات | 1,200 درهم | معتمد من هيئة الصحة بدبي
Executive Summary – UAE-Compliant Molecular Monitoring for CML
- 99.9% Diagnostic Sensitivity – ISO 9001:2015‑accredited laboratory (Cert: INT/EGQ/2509DA/3139) using real‑time quantitative PCR with international scale (IS) calibration.
- Premium Logistics – Hospital‑grade cold‑chain home collection via certified VIP phlebotomists; samples transported at 2‑8 °C within 60 minutes.
- Clinical Guidance – Post‑test telephonic consultation explaining BCR‑ABL1 transcript levels, molecular remission status, and recommended follow‑up, fully aligned with 2026 DHA standards.
- Insurance & Billing – Direct verification of coverage over WhatsApp: +971 54 548 8731. We handle pre‑approvals for leading UAE networks.
Test Overview & Comparison
This highly sensitive blood test measures the BCR‑ABL1 fusion transcript, the molecular hallmark of chronic myeloid leukemia (CML). يقيس هذا الاختبار الجيني مستويات الـ BCR‑ABL1 في الدم لمراقبة فعالية العلاج وتحديد الارتجاع المبكر للمرض. By detecting even one leukemia cell among 100,000 normal cells, it guides targeted therapy decisions (e.g., TKI dose adjustments) and confirms deep molecular response.
| Feature | Our BCR‑ABL1 MRD Test | Closest Alternative (Standard RT‑PCR) |
|---|---|---|
| Methodology | Real‑time quantitative PCR (qPCR) standardized to the International Scale (IS) | Conventional RT‑PCR; may not be IS‑calibrated |
| Sensitivity (MRD depth) | Up to MR4.5 (0.001% IS) – detects 1 CML cell in 100,000 | Typically MR3.0 (0.1% IS) or higher |
| Turnaround Time | 24 hours by phone; 36 hours via email (3rd working day report) | 5–7 working days |
| Sample Requirement | 2–3 mL peripheral whole blood (EDTA tube) – no bone marrow needed | Often requires bone marrow aspirate |
| UAE Regulatory Status | DHA‑listed molecular test, fully compliant with Federal Decree‑Law No. 41 of 2024 | Variable; may lack ISO 9001:2015 certification |
Physician Insight & Safety Protocol
“Molecular monitoring with BCR‑ABL1 qPCR is the cornerstone of modern CML care. A single result must always be interpreted alongside complete blood counts, kinase domain mutation analysis, and adherence history. At ULTA LABS, our integrated tele‑counseling ensures that every patient understands what a 0.01% IS really means before making any treatment changes.”
— Dr. Prabhakar Reddy, DHA License No. 61713011, Consultant Hematologist & Molecular Pathologist
⚠ Medication Warning
Do not discontinue or adjust prescribed tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, etc.) based on this test alone. Always consult your treating oncologist. Abrupt cessation can lead to rapid disease relapse.
🚨 Exclusion Criteria & ER Red Flags
- Recent blood transfusion (<4 weeks) may transiently lower BCR‑ABL1 levels – reschedule if possible.
- Active uncontrolled infection or major surgery in the last 2 weeks – inform the phlebotomist.
- ER Red Flags: Seek immediate emergency care if you experience sudden high fever >38.5°C, uncontrollable bleeding, severe bone pain, or signs of neurological deficit (blast crisis).
- Pregnancy or breastfeeding – test may still be performed but interpretation requires caution; discuss with your physician.
Patient FAQ & Clinical Guidance
Q1: What exactly does the BCR‑ABL1 quantitative test measure?
Snippet killer: It quantifies the BCR‑ABL1 fusion gene transcript in your blood to monitor minimal residual leukemia after CML treatment.
س: ما الذي يقيسه تحليل BCR‑ABL1 الكمي بالضبط؟
ج: يقيس كمية الجين الهجين BCR‑ABL1 في الدم لتقييم البقايا اللوكيمية الدنيا ومتابعة الاستجابة للعلاج بمثبطات التايروسين كيناز.
Q2: How often should I repeat this if I have CML?
Snippet killer: Guidelines recommend every 3 months until a major molecular response, then every 3–6 months to ensure sustained deep remission.
س: كم مرة ينبغي إعادة هذا التحليل لمريض سرطان الدم النقوي المزمن؟
ج: يُوصى بإجرائه كل 3 أشهر حتى تحقيق استجابة جزيئية رئيسية، ثم كل 3–6 أشهر للتأكد من استمرار الهدأة العميقة.
Q3: What does an undetectable result (MR4.5) mean?
Snippet killer: It signifies a deep molecular response with less than 0.001% leukemia, often allowing consideration of treatment‑free remission after medical consultation.
س: ماذا تعني النتيجة غير القابلة للكشف (MR⁴·⁵)؟
ج: تدل على استجابة جزيئية عميقة حيث تبقى أقل من 0.001% من الخلايا اللوكيمية، مما قد يسمح بمناقشة إيقاف العلاج تحت إشراف الطبيب.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians